VRDN241220P30000
- 0.00
- 0.000.00%
Viridian Therapeutics Newsroom
Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024
Is Viridian Therapeutics (NASDAQ:VRDN) Weighed On By Its Debt Load?
Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN), DocGo (DCGO) and Alkermes (ALKS)
RBC Capital Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $44
Express News | RBC Capital Reiterates Outperform on Viridian Therapeutics, Maintains $44 Price Target
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Graves' Disease Pipeline Drug Research Report 2024 Featuring Viridian Therapeutics, Immunovant Sciences, Apitope International, Sling Therapeutics, and Novartis
This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday
Needham Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $38
Needham Reiterates Buy on Viridian Therapeutics, Maintains $38 Price Target
TD Cowen Initiates Viridian Therapeutics(VRDN.US) With Buy Rating
TD Cowen Initiates Coverage On Viridian Therapeutics With Buy Rating
Viridian Therapeutics: Buy Rating Due to Promising TED Therapy and Market Potential
Viridian Therapeutics, Inc. (VRDN): This Small-Cap Stock Is Ready To Explode
Viridian Therapeutics (VRDN) Pioneering Breakthroughs in Thyroid Eye Disease
Viridian Therapeutics Analyst Ratings
Viridian Therapeutics: Promising FcRn Inhibitor Developments and Strong Buy Recommendation
H.C. Wainwright Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $34
In-Depth Examination Of 11 Analyst Recommendations For Viridian Therapeutics